Skip to Content

Angion Biomedica Corp.

Merger

  • Date:
  • 1/17/2023
  • Company Name:
  • Angion Biomedica Corp.
  • Stock Symbol:
  • ANGN
  • Company Name - Buyer:
  • Elicio
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 1/17/2023

Case Finder

Locate any case using the tools below.

NEW YORK, January 17, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Angion Biomedica Corp (NASDAQ: ANGN) (“Angion”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Elicio.

On January 17, 2023, Angion announced that it had entered into an agreement to be acquired by Elicio in an all-stock deal. Pursuant to the merger agreement, Elicio will merge with a wholly-owned subsidiary of Angion, and stockholders of Elicio will receive newly issued shares of Angion common stock. Current Angion stockholders are expected to own approximately 34.5% of the newly combined company while Elicio stockholders will own 65.5% of the newly combined company, in each case on a fully diluted basis. The deal is expected to close in the second quarter of 2023.

Bragar Eagel & Squire is concerned that Angion’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Angion’s stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Angion Biomedica Corp.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: